Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei,Andrew H. Wei,Pau Montesinos,Pau Montesinos,VV Ivanov,Courtney D. DiNardo,Jan Novák,Kamel Laribi,Inho Kim,Don A. Stevens,Walter Fiedler,Maria Pagoni,Olga Samoilova,Yu Hu,Achilles Anagnostopoulos,Julie Bergeron,Jing-Zhou Hou,Vidhya Murthy,Takahiro Yamauchi,Andrew McDonald,Brenda Chyla,Sathej Gopalakrishnan,Qi Jiang,Wellington Luiz Mendes,John Hayslip,Panayiotis Panayiotidis +25 more
Reads0
Chats0
TLDR
In this article, patients were randomized 2:1 to venetoclax plus low-dose cytarabine (LDAC) or placebo (n = 68) in 28-day cycles, plus LDAC on days 1 to 10.About:
This article is published in Blood.The article was published on 2020-06-11 and is currently open access. It has received 395 citations till now. The article focuses on the topics: Venetoclax.read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel.
Hartmut Döhner,Andrew H. Wei,Frederick R. Appelbaum,Charles Craddock,Courtney D. DiNardo,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Lucy A. Godley,Robert P. Hasserjian,Richard A. Larson,Ross Levine,Yasushi Miyazaki,Dietger Niederwieser,Gert J. Ossenkoppele,Christoph Röllig,Jorge Sierra,Eytan M. Stein,Martin S. Tallman,Hwei-Fang Tien,Jianxiang Wang,Agnieszka Wierzbowska,Bob Löwenberg +22 more
TL;DR: This update includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations for acute myeloid leukemia in adults, which are widely recognized among physicians and investigators.
Journal ArticleDOI
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chong Chyn Chua,Chong Chyn Chua,Andrew W. Roberts,Andrew W. Roberts,Andrew W. Roberts,John V. Reynolds,Chun Yew Fong,Stephen B. Ting,Jessica M. Salmon,Sarah MacRaild,Sarah MacRaild,Adam Ivey,Ing Soo Tiong,Ing Soo Tiong,Shaun Fleming,Shaun Fleming,Fiona C. Brown,Sun Loo,Ian J. Majewski,Ian J. Majewski,Stefan K. Bohlander,Andrew H. Wei,Andrew H. Wei +22 more
TL;DR: Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).
Journal ArticleDOI
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs.
Sarah T Diepstraten,Mary Ann Anderson,Peter E. Czabotar,Peter E. Czabotar,Guillaume Lessene,Guillaume Lessene,Andreas Strasser,Andreas Strasser,Gemma L. Kelly,Gemma L. Kelly +9 more
TL;DR: A review of BH3-mimetic drugs targeting various prosurvival BCL-2 family proteins and emerging data regarding primary and acquired resistance to these agents and approaches that may overcome this can be found in this article.
Journal ArticleDOI
Towards precision medicine for AML
TL;DR: A review of the state of the art for acute myeloid leukaemia can be found in this article, where the authors discuss the current state of precision medicine for AML, including both the potential to improve patient outcomes and the related challenges.
Journal ArticleDOI
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Arnold Bolomsky,Meike Vogler,Murat Cem Köse,Caroline A. Heckman,Grégory Ehx,Heinz Ludwig,Jo Caers +6 more
TL;DR: The major functions of MCL-1 are summarized with a special focus on cancer, insights into its different roles in solid vs. hematological tumors are provided and an update is given about the (pre)clinical development program of state-of-the-art M CL-1 targeting compounds.
References
More filters
Journal ArticleDOI
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Jürgen Thiele,Michael J. Borowitz,Michelle M. Le Beau,Clara D. Bloomfield,Mario Cazzola,James W. Vardiman +8 more
TL;DR: The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.
Journal ArticleDOI
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
TL;DR: An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.
Journal ArticleDOI
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D. Cheson,John M. Bennett,Kenneth J. Kopecky,Thomas Büchner,Cheryl L. Willman,Elihu H. Estey,Charles A. Schiffer,Hartmut Doehner,Martin S. Tallman,T. Andrew Lister,Francesco Lo-Coco,Roel Willemze,Andrea Biondi,Wolfgang Hiddemann,Richard A. Larson,Bob Löwenberg,Miguel A. Sanz,David R. Head,Ryuzo Ohno,Clara D. Bloomfield +19 more
TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.
Journal ArticleDOI
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts,Matthew S. Davids,John M. Pagel,Brad S. Kahl,Soham D. Puvvada,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Jennifer R. Brown,Lori A. Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,William G. Wierda,John F. Seymour,John F. Seymour +20 more
TL;DR: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
Journal ArticleDOI
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
Courtney D. DiNardo,Keith W. Pratz,Vinod Pullarkat,Brian A. Jonas,Martha Arellano,Pamela S. Becker,Pamela S. Becker,Olga Frankfurt,Marina Konopleva,Andrew H. Wei,Hagop M. Kantarjian,Tu Xu,Wan Jen Hong,Brenda Chyla,Jalaja Potluri,Daniel A. Pollyea,Anthony Letai +16 more
TL;DR: The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML and achieved complete remission (CR) + CR with incomplete count recovery (CRi).
Related Papers (5)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
Courtney D. DiNardo,Brian A. Jonas,Vinod Pullarkat,Michael J. Thirman,Jacqueline S. Garcia,Andrew H. Wei,Marina Konopleva,Hartmut Döhner,Anthony Letai,Pierre Fenaux,Elizabeth A. Koller,Violaine Havelange,Brian Leber,Jordi Esteve,Jianxiang Wang,Vlatko Pejša,Roman Hájek,Kimmo Porkka,Árpád Illés,David Lavie,Roberto M. Lemoli,Kazuhito Yamamoto,Sung-Soo Yoon,Jun-Ho Jang,Su-Peng Yeh,Mehmet Turgut,Wan-Jen Hong,Ying Zhou,Jalaja Potluri,Keith W. Pratz +29 more
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Döhner,Elihu H. Estey,David Grimwade,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Hervé Dombret,Benjamin L. Ebert,Pierre Fenaux,Richard A. Larson,Ross L. Levine,Francesco Lo-Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel A. Sanz,Jorge Sierra,Martin S. Tallman,Hwei-Fang Tien,Andrew H. Wei,Andrew H. Wei,Bob Löwenberg,Clara D. Bloomfield +22 more
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone,Sumithra J. Mandrekar,Ben L. Sanford,Kristina Laumann,Susan Geyer,Clara D. Bloomfield,Christian Thiede,Thomas W. Prior,Konstanze Döhner,Guido Marcucci,Francesco Lo-Coco,Rebecca B. Klisovic,Andrew H. Wei,Jorge Sierra,Miguel A. Sanz,Joseph Brandwein,Theo de Witte,Dietger Niederwieser,Frederick R. Appelbaum,Bruno C. Medeiros,Martin S. Tallman,Jürgen Krauter,Richard F. Schlenk,Arnold Ganser,Hubert Serve,Gerhard Ehninger,Sergio Amadori,Richard A. Larson,Hartmut Döhner +28 more
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva,Daniel A. Pollyea,Jalaja Potluri,Brenda Chyla,Leah Hogdal,Todd Busman,Evelyn McKeegan,Ahmed Salem,Ming Zhu,Justin L. Ricker,William Blum,Courtney D. DiNardo,Tapan M. Kadia,Martin Dunbar,Rachel Kirby,Nancy Falotico,Joel D. Leverson,Rod A. Humerickhouse,Mack Mabry,Richard Stone,Hagop M. Kantarjian,Anthony Letai +21 more